Statins Show Promise in Reducing COVID-19 Severity, Recovery Time

Strategic Insights -

Researchers at UC San Diego Health have reported that statins, widely used cholesterol-lowering medications, are associated with a reduced risk of developing severe COVID-19 disease and faster recovery times. The findings, published in September 2020, suggest that statins may inhibit SARS-CoV-2 infection through their anti-inflammatory effects and binding capabilities. A second study, also published in September 2020, has shed light on the mechanism behind statins' protective effect, revealing that removing cholesterol from cell membranes prevents the coronavirus from entering cells.

Key Takeaways:

  • Statins, widely used cholesterol-lowering medications, are associated with a reduced risk of developing severe COVID-19 disease and faster recovery times.
  • Statin use prior to hospital admission for COVID-19 was associated with a more than 50% reduction in risk of developing severe COVID-19 compared to those with COVID-19 but not taking statins.
  • Patients with COVID-19 who were taking statins prior to hospitalization also recovered faster than those not taking the cholesterol-lowering medication.
  • The protective effect of statins may be due to their anti-inflammatory effects and binding capabilities.
  • Removing cholesterol from cell membranes prevents the coronavirus from entering cells, as discovered by a study published in The EMBO Journal in September 2020.
  • The study found that a molecule called CH25H, which modifies cholesterol, plays a key role in inhibiting SARS-CoV-2 infection.
  • The researchers plan to continue optimizing CH25H as a potential antiviral agent, potentially leading to a therapeutic that could work even better than statins.

Statistics:

  • 27% of patients with COVID-19 were actively taking statins on admission.
  • 21% of patients with COVID-19 were on an ACE inhibitor, and 12% were on an ARB.
  • The median length of hospital stay for patients with COVID-19 was 9.7 days.
  • Statin use prior to hospital admission for COVID-19 was associated with a more than 50% reduction in risk of developing severe COVID-19.

Sources:

  • Daniels, L., et al. (2020). Statin use and COVID-19 outcomes: a retrospective analysis of electronic medical records. American Journal of Cardiology, 126(9), 1233-1238.
  • Rana, T. M., et al. (2020). CH25H inhibitor suppresses SARS-CoV-2 infection. The EMBO Journal, e102437.